Cargando…
Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)
BACKGROUND. GSK3532795 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor that targets HIV-1 Gag, inhibiting the final protease cleavage between capsid protein p24 and spacer protein-1, producing immature, noninfectious virions. METHODS. This was a phase 2a, rand...
Autores principales: | Hwang, Carey, Schürmann, Dirk, Sobotha, Christian, Boffito, Marta, Sevinsky, Heather, Ray, Neelanjana, Ravindran, Palanikumar, Xiao, Hong, Keicher, Christian, Hüser, Andreas, Krystal, Mark, Dicker, Ira B., Grasela, Dennis, Lataillade, Max |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848258/ https://www.ncbi.nlm.nih.gov/pubmed/28369211 http://dx.doi.org/10.1093/cid/cix239 |
Ejemplares similares
-
Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
por: Dicker, Ira, et al.
Publicado: (2019) -
The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates
por: Ray, Neelanjana, et al.
Publicado: (2017) -
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009) -
Correction: Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
Publicado: (2019) -
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)